Unique ID issued by UMIN | UMIN000026640 |
---|---|
Receipt number | R000030595 |
Scientific Title | Predictive factors associated with virological response in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients |
Date of disclosure of the study information | 2017/03/23 |
Last modified on | 2019/03/25 10:19:39 |
Predictive factors associated with virological response in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients
Virological response in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients
Predictive factors associated with virological response in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients
Virological response in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients
Japan |
Chronic hepatitis C
Hepato-biliary-pancreatic medicine |
Others
NO
Inspection of the curative effect and to confirm the predictive factors associated with virological response and in Ombitasvir/Paritaprevir/Ritonavir/Ribavirin combination therapy for genotype2a infected chronic hepatitis C patients.
Safety,Efficacy
Sustained virological response rate
1. Change in serum HCV RNA during treatment and follow-up duration
2. Change in hematological and biochemical test during treatment and follow-up duration
3. Change in Mac-2 Binding Protein,hyaluronic acid, type IV collagen,gamma globulin during treatment and follow-up duration.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Treat with Ombitasvir/Paritaprevir /Ritonavir/Ribavirin combination therapy.
18 | years-old | <= |
85 | years-old | > |
Male and Female
Case of introducing ombitasvir/paritaprevir/ritonavir/ribavirin combination therapy for Genotype 2 type C chronic liver disease
1History of allergy to Ombitasvir/Paritaprevir /Ritonavir/Ribavirin
2Liver cirrhosis
3Patients with creatinine clearance less than 50 ml / min
4Pregnant woman or lactating mother
5Hepatocellular carcinoma, or other malignant tumor
6Judged by investigator not to be appropriate for inclusion in this study
300
1st name | Masanori |
Middle name | |
Last name | Atsukawa |
Nippon Medical School Chiba Hokusoh Hospital
Division of Gastroenterology
270-1694
1715 Kamagari Inzai Chiba
0476-99-1111
atsukawa-nms@umin.ac.jp
1st name | Tomomi |
Middle name | |
Last name | Okubo |
Nippon Medical School Chiba Hokusoh Hospital
Division of Gastroenterology
2701694
1715 Kamagari Inzai Chiba
0476-99-1111
atsukawa-nms@umin.ac.jp
Nipppon Medical School Chiba Hokusoh Hospital
none
Self funding
Nippon Medical School Hospital
Nippon Medical School Musashi Kosugi Hospital
The Jikei University Hospital
Otakanomori Hospital
Hakujikai Healthcare foundation
Tokyo Metropolitan Bokutoh Hospital
Tokyo Medical University Ibaraki Medical Center
Shinmatsudo Central General Hospital
Japanese Red Cross Narita Hospital
Nippon Medical School Chiba Hokusoh Hospital institutional review board
1715, Kamakari, Inzai, Chiba, Japan
0476-99-1111
araraki@nms.ac.jp
NO
2017 | Year | 03 | Month | 23 | Day |
Published
98
Completed
2017 | Year | 01 | Month | 12 | Day |
2017 | Year | 01 | Month | 12 | Day |
2017 | Year | 01 | Month | 16 | Day |
2018 | Year | 12 | Month | 28 | Day |
2017 | Year | 03 | Month | 22 | Day |
2019 | Year | 03 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030595